ARTERIUS
Arterius Limited is developing a novel next-generation polymer-based Bio-resorbable Coronary Scaffold (BRS), more commonly known as a ‘stent’. The bio-resorbable attribute allows the stent to dissolve over time, typically 12–24 months, before being absorbed by the body. Therefore, there is no requirement to physically remove the stent. The Company’s solution offers a huge opportunity to minimise the frequency of surgery or medical interventions and could give patients a better post-operative quality of life.
ARTERIUS
Social Links:
Industry:
Biotechnology Health Care Life Science Medical Medical Device Pharmaceutical
Founded:
2009-01-01
Address:
Leeds, Leeds, United Kingdom
Country:
United Kingdom
Website Url:
http://www.arterius.co.uk
Total Employee:
1+
Status:
Active
Contact:
0113 4264300
Total Funding:
349 K USD
Technology used in webpage:
JPlayer CreativeWork Schema
Similar Organizations
Arterial Remodeling Technologies
Arterial Remodeling Technologies develops bioresorbable peripheral and coronary polymer stents.
LevOss
LevOss is developing a biodegradable material (polymer) embedded with a Nano mesh.
Mumo
Share your secure health information anywhere in the world with anyone you want.
Oppilotech
Developing the next generation of antibiotics with novel mechanisms of action.
PCI Pharma Services
PCI Pharma Services is a provider of outsourced services to the global pharmaceutical market.
Current Employees Featured
Founder
Investors List
Innovate UK
Innovate UK investment in Grant - Arterius
Deepbridge Capital
Deepbridge Capital investment in Seed Round - Arterius
Official Site Inspections
http://www.arterius.co.uk
- Host name: 76.76.21.21
- IP address: 76.76.21.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Arterius"
The Arterius Stent | Arterius
At Arterius we support global healthcare innovators to develop next-generation, patient-centric products. ... Innovate UK. University of Southampton. University of Bradford. University of Nottingham. University of Bristol. Imperial College. …See details»
The Arterius Stent | Arterius
Arterius is an innovator in polymer technologies for medical devices with current applications in vascular intervention. Our team Arterius’ talented team has exceptional expertise in medical …See details»
The Arterius Stent | Arterius
He has over 40 years of experience in Biomaterials and Medical Devices. Prior to setting up Arterius, he was a co-founder of PolyBioMed Ltd in 1996, serving as Technical Director before …See details»
Arterius - Crunchbase Company Profile & Funding
Organization. Arterius . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Arterius developing …See details»
Arterius Company Profile 2024: Valuation, Funding
When was Arterius founded? Arterius was founded in 2009. Where is Arterius headquartered? Arterius is headquartered in Leeds, United Kingdom. What is …See details»
Arterius - Company Profile - Tracxn
Nov 27, 2024 Arterius is a medical device company developing a coronary stent. The company claims to be developing a product that will have superior design and use a different material …See details»
ARTERIUS LIMITED Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for ARTERIUS LIMITED of LEEDS. Get the latest business insights from Dun & Bradstreet. D&B Business …See details»
Arterius Ltd: Contact Details and Business Profile
Arterius Ltd. was established in 2009 to exploit opportunities in the multi-billion dollar coronary stent market. The Arteriosorb™ Biodegradable Scaffold is produced using a proprietary …See details»
ARTERIUS LIMITED - Companies House
Company Overview for ARTERIUS LIMITED (06981739) Filing history for ARTERIUS LIMITED (06981739) People for ARTERIUS LIMITED (06981739) More for ARTERIUS LIMITED …See details»
The Arterius Stent | Arterius
Arterius Limited Mayesbrook House Lawnswood Business Park Redvers Close Leeds LS16 6QY Telephone: 0113 4264300 Follow us: ...See details»
Pioneering Stent Developer To Scale Up Research
Dec 3, 2024 Leeds-based Arterius was established by Dr Kadem Al-Lamee and Alistair Taylor to research and develop innovative medical devices for the £6.3bn coronary stent market. Coronary artery disease is caused by blockages in the …See details»
Arterius - VentureRadar
Arterius Ltd. is developing a next-generation bioresorbable cardiovascular scaffold (stent), “ArterioSorb™, ” with an emerging market-leading clinical profile, intended to match the ease …See details»
Arterius - FS Ventures
Arterius has developed a polymer-based bioresorbable scaffold (or “BRS”) ArterioSorb™ that is intended to: Match the ease of delivery of Bare Metal Stent (BMS) and Drug Eluting Stent …See details»
Arterius - Overview, News & Similar companies | ZoomInfo.com
Arterius contact info: Phone number: +44 1134264300 Website: www.arterius.co.uk What does Arterius do? Arterius Limited has been awarded a research grant from the European Union …See details»
The Arterius Stent | Arterius
[email protected]. Read more. 30th November 2023. Arterius Ltd receives ISO 13485 Certification. 22nd July 2023. Arterius presents at World Congress of Smart Materials …See details»
Arterius (United Kingdom) - Wikidata
Arterius (United Kingdom) (Q56583784) From Wikidata. Jump to navigation Jump to search. company in Leeds, United Kingdom. edit. Language Label Description Also known as; English: …See details»
ARTERIUS LIMITED, West Park, United Kingdom, Mayesbrook …
Find company information, contact details, financial data & company linkages for ARTERIUS LIMITED of West Park, United Kingdom.See details»
The Arterius Stent | Arterius
Nov 30, 2023 ARTERIUS PRESS RELEASE Date: 30th November 2023. Arterius Limited, a Leeds-based, UK company developing innovative medical devices with a focus on next …See details»
Arterius Ltd. (Arterius Ltd.) - 药物管线_专利_临床试验_投融营收
The in-silico results demonstrated good predictions of final shape for the baseline scaffold design. Percentage recoil and radial strength were predicted to be, respectively, 2.8 and 1.7 times …See details»